Nothing said here yet.
to join the conversation.
| Stern SadieEVP Chief People & Culture Off | Sell | 2,565 | $201.7K | Tue, Oct 27 |
| Brown Michael JonEVP Chief Legal Compliance Off | Sell | 1,700 | $145.3K | Thu, Oct 15 |
| Stern SadieEVP Chief People & Culture Off | Sell | 2,565 | $221.0K | Mon, Sep 28 |
| AUGUSTINOS NICHOLASDirector | Sell | 6,539 | $549.5K | Tue, Sep 15 |
| Brown Michael JonEVP Chief Legal Compliance Off | Sell | 1,700 | $142.9K | Tue, Sep 15 |
| AUGUSTINOS NICHOLASDirector | Sell | 1,550 | $130.2K | Mon, Sep 14 |
| Sylvain Jereme MEVP, Chief Financal Officer | Sell | 3,638 | $302.9K | Thu, Sep 10 |
| Stern SadieEVP Chief People & Culture Off | Sell | 2,565 | $226.7K | Thu, Aug 27 |
| SAYER KEVIN RExecutive Chair | Sell | 19,308 | $1.7M | Thu, Aug 20 |
| SAYER KEVIN RExecutive Chair | Sell | 7,351 | $667.3K | Thu, Aug 20 |
| SAYER KEVIN RExecutive Chair | Sell | 97 | $8.9K | Thu, Aug 20 |
| Brown Michael JonEVP Chief Legal Compliance Off | Sell | 1,700 | $156.3K | Fri, Aug 14 |
| Tina Smith | Sell | $175.0K | Thu, May 7 | Sun, May 10 |
| Tina Smith | Sell | $175.0K | Wed, Apr 29 | Sun, May 10 |
DexCom has enjoyed a strong run over the past year, yet the share price still leaves a basic question on the table for investors who care about cash flows.
DexCom (NasdaqGS:DXCM) has launched its Dexcom G7 15 Day Continuous Glucose Monitoring System in Canada, following Health Canada authorization. The Dexcom G7 15 Day is described as the longest duration CGM system currently available to Canadian users.
Dexcom, known for its G-series of diabetes wearables, topped September-quarter expectations late Thursday, leading to a guidance hike.
DexCom (DXCM) posted better-than-expected Q3 results and raised its 2026 revenue guidance, and US sh
DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
Moby summary of DexCom, Inc.'s Q3 2026 earnings call
SAN DIEGO (AP) — SAN DIEGO (AP) — DexCom Inc. (DXCM) on Thursday reported third-quarter profit of $275.
DexCom (NASDAQ:DXCM) reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported higher profitability.
Medical device company DexCom (NASDAQ:DXCM) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 11.2% year on year to $1.34 billion.